Pharming Group Current Valuation vs. Net Income
| PHAR Stock | USD 17.92 0.52 2.82% |
For Pharming Group profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Pharming Group to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Pharming Group NV utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Pharming Group's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Pharming Group NV over time as well as its relative position and ranking within its peers.
Check out Your Equity Center. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pharming Group. If investors know Pharming will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pharming Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.61) | Revenue Per Share | Quarterly Revenue Growth 0.3 | Return On Assets | Return On Equity |
The market value of Pharming Group NV is measured differently than its book value, which is the value of Pharming that is recorded on the company's balance sheet. Investors also form their own opinion of Pharming Group's value that differs from its market value or its book value, called intrinsic value, which is Pharming Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pharming Group's market value can be influenced by many factors that don't directly affect Pharming Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pharming Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pharming Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pharming Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Pharming Group NV Net Income vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Pharming Group's current stock value. Our valuation model uses many indicators to compare Pharming Group value to that of its competitors to determine the firm's financial worth. Pharming Group NV is regarded fourth in current valuation category among its peers. It is considered to be number one stock in net income category among its peers . Pharming Group reported last year Net Loss of (13.62 Million). Comparative valuation analysis is a catch-all technique that is used if you cannot value Pharming Group by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Pharming Current Valuation vs. Competition
Pharming Group NV is regarded fourth in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 11.17 Billion. Pharming Group retains roughly 1.2 Billion in current valuation claiming about 11% of equities under Health Care industry.
Pharming Net Income vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Pharming Group |
| = | 1.2 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Pharming Group |
| = | (8.49 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Pharming Net Income Comparison
Pharming Group is currently under evaluation in net income category among its peers.
Pharming Group Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Pharming Group, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Pharming Group will eventually generate negative long term returns. The profitability progress is the general direction of Pharming Group's change in net profit over the period of time. It can combine multiple indicators of Pharming Group, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -240.3 K | -228.3 K | |
| Operating Income | -9.9 M | -9.4 M | |
| Income Before Tax | -9.8 M | -10.3 M | |
| Total Other Income Expense Net | 116.1 K | 121.9 K | |
| Net Loss | -9.8 M | -10.3 M | |
| Income Tax Expense | 3.9 M | 4 M | |
| Net Interest Income | -5.8 M | -6.1 M | |
| Interest Income | 5.6 M | 3.1 M | |
| Net Loss | -13.6 M | -12.9 M | |
| Net Income Applicable To Common Shares | 15.7 M | 8.3 M | |
| Change To Netincome | -3.2 M | -3.1 M | |
| Net Loss | (0.01) | (0.01) | |
| Income Quality | 0.16 | 0.14 | |
| Net Income Per E B T | 1.22 | 1.16 |
Pharming Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Pharming Group. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Pharming Group position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Pharming Group's important profitability drivers and their relationship over time.
Pharming Group Earnings Estimation Breakdown
The calculation of Pharming Group's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Pharming Group is estimated to be 0.015875 with the future projection ranging from a low of 0.015 to a high of 0.01675. Please be aware that this consensus of annual earnings estimates for Pharming Group NV is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.01 Lowest | Expected EPS | 0.02 Highest |
Pharming Group Earnings Projection Consensus
Suppose the current estimates of Pharming Group's value are higher than the current market price of the Pharming Group stock. In this case, investors may conclude that Pharming Group is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Pharming Group's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 3 | 52.73% | 0.0 | 0.015875 | 0.0 |
Pharming Group Earnings per Share Projection vs Actual
Actual Earning per Share of Pharming Group refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Pharming Group NV predict the company's earnings will be in the future. The higher the earnings per share of Pharming Group, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Pharming Group Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Pharming Group, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Pharming Group should always be considered in relation to other companies to make a more educated investment decision.Pharming Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Pharming Group's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-10-22 | 2025-09-30 | -0.125 | 0.1 | 0.225 | 180 | ||
2025-07-31 | 2025-06-30 | -0.0125 | 0.01 | 0.0225 | 180 | ||
2025-05-06 | 2025-03-31 | -0.025 | -0.022 | 0.003 | 12 | ||
2025-03-12 | 2024-12-31 | 0.0085 | 0.005 | -0.0035 | 41 | ||
2024-10-24 | 2024-09-30 | -0.0025 | -0.0153 | -0.0128 | 512 | ||
2024-08-01 | 2024-06-30 | -0.002 | -0.0177 | -0.0157 | 785 | ||
2024-05-08 | 2024-03-31 | 0.007 | -0.1851 | -0.1921 | 2744 | ||
2024-03-14 | 2023-12-31 | 0.0045 | -0.0406 | -0.0451 | 1002 | ||
2023-10-26 | 2023-09-30 | 0.01 | 0.005 | -0.005 | 50 | ||
2023-08-03 | 2023-06-30 | 0.01 | 0.01 | 0.0 | 0 | ||
2023-05-11 | 2023-03-31 | -0.17 | -0.17 | 0.0 | 0 | ||
2023-03-16 | 2022-12-31 | -0.21 | -0.205 | 0.005 | 2 | ||
2022-10-27 | 2022-09-30 | 0.4 | 0.4 | 0.0 | 0 | ||
2022-08-04 | 2022-06-30 | 0.22 | 0.215 | -0.005 | 2 | ||
2022-05-12 | 2022-03-31 | 0.05 | 0.05 | 0.0 | 0 | ||
2022-03-17 | 2021-12-31 | 0.02 | 0.015 | -0.005 | 25 | ||
2021-10-28 | 2021-09-30 | 0.0414 | -5.0E-4 | -0.0419 | 101 | ||
2021-08-05 | 2021-06-30 | 0.1 | 0.0524 | -0.0476 | 47 | ||
2021-05-13 | 2021-03-31 | 0.16 | 0.157 | -0.003 | 1 | ||
2021-03-04 | 2020-12-31 | 0.11 | 0.1144 | 0.0044 | 4 | ||
2020-10-29 | 2020-09-30 | 0.12 | 0.0132 | -0.1068 | 89 | ||
2020-07-30 | 2020-06-30 | 0.15 | 0.0117 | -0.1383 | 92 | ||
2020-05-14 | 2020-03-31 | 0.12 | 0.0159 | -0.1041 | 86 | ||
2020-03-05 | 2019-12-31 | 0.2 | 0.0121 | -0.1879 | 93 | ||
2019-10-24 | 2019-09-30 | 0.18 | 0.0203 | -0.1597 | 88 | ||
2019-07-26 | 2019-06-30 | 0.12 | 0.0173 | -0.1027 | 85 | ||
2019-06-30 | 2019-03-31 | 0 | 0.0114 | 0.0114 | 0 | ||
2019-03-31 | 2018-12-31 | 0 | 0.0112 | 0.0112 | 0 | ||
2018-12-31 | 2018-09-30 | 0 | 0.0261 | 0.0261 | 0 | ||
2018-09-30 | 2018-06-30 | 0 | 0.0084 | 0.0084 | 0 | ||
2018-06-30 | 2018-03-31 | 0 | 0.0057 | 0.0057 | 0 | ||
2018-03-31 | 2017-12-31 | 0 | 0.0099 | 0.0099 | 0 | ||
2017-12-31 | 2017-09-30 | 0 | -0.0868 | -0.0868 | 0 | ||
2017-09-30 | 2017-06-30 | 0 | -0.0171 | -0.0171 | 0 | ||
2017-06-30 | 2017-03-31 | 0 | -0.0591 | -0.0591 | 0 | ||
2017-03-31 | 2016-12-31 | 0 | -0.0128 | -0.0128 | 0 | ||
2016-12-31 | 2016-09-30 | 0 | -0.0183 | -0.0183 | 0 | ||
2016-09-30 | 2016-06-30 | 0 | -0.0101 | -0.0101 | 0 | ||
2016-06-30 | 2016-03-31 | 0 | -0.0089 | -0.0089 | 0 | ||
2016-03-31 | 2015-12-31 | 0 | -0.0091 | -0.0091 | 0 | ||
2015-12-31 | 2015-09-30 | 0 | -0.0119 | -0.0119 | 0 | ||
2015-09-30 | 2015-06-30 | 0 | -0.0055 | -0.0055 | 0 | ||
2015-06-30 | 2015-03-31 | 0 | -0.0072 | -0.0072 | 0 | ||
2015-03-31 | 2014-12-31 | 0 | -0.0032 | -0.0032 | 0 | ||
2014-12-31 | 2014-09-30 | 0 | 0.0464 | 0.0464 | 0 | ||
2014-09-30 | 2014-06-30 | 0 | -0.0031 | -0.0031 | 0 | ||
2014-06-30 | 2014-03-31 | 0 | -0.0058 | -0.0058 | 0 | ||
2014-03-31 | 2013-12-31 | 0 | -0.0606 | -0.0606 | 0 | ||
2013-12-31 | 2013-09-30 | 0 | -0.0168 | -0.0168 | 0 | ||
2013-09-30 | 2013-06-30 | 0 | -0.0233 | -0.0233 | 0 | ||
2013-06-30 | 2013-03-31 | 0 | -0.0127 | -0.0127 | 0 | ||
2013-03-31 | 2012-12-31 | 0 | -0.0585 | -0.0585 | 0 | ||
2012-12-31 | 2012-09-30 | 0 | 0.0012 | 0.0012 | 0 | ||
2012-09-30 | 2012-06-30 | 0 | -0.129 | -0.129 | 0 | ||
2012-06-30 | 2012-03-31 | 0 | -0.2074 | -0.2074 | 0 | ||
2012-03-31 | 2011-12-31 | 0 | -0.1608 | -0.1608 | 0 | ||
2011-12-31 | 2011-09-30 | 0 | -0.11 | -0.11 | 0 |
Use Pharming Group in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pharming Group position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pharming Group will appreciate offsetting losses from the drop in the long position's value.Pharming Group Pair Trading
Pharming Group NV Pair Trading Analysis
The ability to find closely correlated positions to Pharming Group could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pharming Group when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pharming Group - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pharming Group NV to buy it.
The correlation of Pharming Group is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pharming Group moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pharming Group NV moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pharming Group can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Pharming Group position
In addition to having Pharming Group in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Blend Funds Thematic Idea Now
Small Blend Funds
Fund or Etfs that invest in stocks of small to mid-sized entities that have characteristics of both growth and value companies. The Small Blend Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Blend Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.